US 9,808,520 B1
Rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate
Manuel V. Borca, Westbrook, CT (US); Douglas P. Gladue, Guilford, CT (US); Lauren G. Holinka-Patterson, Deep River, CT (US); Guillermo R. Risatti, Westbrook, CT (US); and Vivian K. O'Donnell, Old Saybrook, CT (US)
Assigned to The United States of America as represented by The Secretary of Agriculture, Washington, DC (US); and The University of Connecticut, Farmington, CT (US)
Filed by The United States of America, as Represented by the Secretary of Agriculture, Washington, DC (US); and The University of Connecticut, Storrs, CT (US)
Filed on Jul. 1, 2016, as Appl. No. 15/200,407.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); C12Q 1/70 (2006.01); G01N 33/569 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [C12N 7/00 (2013.01); C12Q 1/701 (2013.01); G01N 33/56983 (2013.01); A61K 2039/5256 (2013.01); C12N 2710/12021 (2013.01); C12N 2710/12034 (2013.01); C12N 2710/12071 (2013.01); G01N 2333/01 (2013.01)] 5 Claims
 
1. A recombinant ASFV-G (African Swine Fever Virus-Georgia 2007 isolate) mutant, the mutant ASFV-G Δ9GL/ΔUK virus, comprising cDNA encoding mutant ASFV-G Δ9GL/ΔUK polypeptides wherein the mutant cDNA comprises two deletions, a deletion of 173 nucleotides resulting in a mutant 9GL protein comprising 58 fewer amino acids than the non-mutated, wild-type 9GL protein of ASFV-G, amino acids #11 to #68 being deleted, and a second deletion of 255 nucleotides resulting in a mutant UK protein comprising 85 fewer amino acids than the non-mutation, wild-type UK protein of ASFV-G, amino acids #1 to #85 being deleted.